尿激酶和瑞替普酶治疗急性心肌梗死溶栓效果比较分析.docVIP

尿激酶和瑞替普酶治疗急性心肌梗死溶栓效果比较分析 　　[摘要] 目的 分析尿激酶和瑞替普酶对急性心肌梗死（AMI）溶栓治疗的效果。 方法 回顾性分析我院2011年3月～2013年4月期间收治的78例急性心肌梗死患者的临床资料，将其分为对照组与治疗组，对照组采用尿激酶治疗，治疗组采用瑞替普酶治疗，比较分析两组患者的血管再通率、死亡率以及并发症等。结果 对照组和治疗组患者的血管再通率分别为53.8%、94.9%；死亡率分别为7.7%、0%；出血并发症率分别为30.8%、17.9%，两组比较，治疗组血管再通时间早、再通比例高，差异有统计学意义（P0.05）。治疗组患者在溶栓后60 min的血管再通率为64.1%、溶栓后90 min的血管再通率为94.9%、溶栓后120 min的血管再通率为97.4%，与对照组比较差异明显，差异有统计学意义（P0.05）。 结论 采用瑞替普酶治疗急性心肌梗死冠脉的再通时间早、冠脉再通率高，且药物维持时间长，患者不良反应较少，是临床一种高效、安全的溶栓药物，值得推广应用。 　　[关键词] 尿激酶；瑞替普酶；急性心肌梗死；溶栓治疗 　　[中图分类号] R542.22 [文献标识码] B [文章编号] 1673-9701（2014）17-0059-03 　　Comparative analysis of fibrinolytic therapy effect of urokinase and reteplase at enzyme in the treatment of acute myocardial infarction 　　SHANG Yu 　　Department of Cardiology， Xifeng County First Hospital in Liaoning Province， Xifeng 112400， China 　　[Abstract] Objective To study and analyze the fibrinolytic therapy effect of urokinase and reteplase in the treatment of acute myocardial infarction（AMI）. Methods The clinical data of 78 cases of patients with acute myocardial infarction（AMI） who had been treated in our hospital from March 2011 to April 2013 were retrospectively analyzed， they were divided into control group and treatment group on the average， the control group were given urokinase， and the treatment group were given reteplase treatment， then the blood vessels in the pass rate， mortality and complications， and so on of the two groups of patients were comparatively analyzed. Results The vascular rate of the control group and treatment group of patients were 53.8%， 94.9% respectively； And the mortality rates were 7.7%， 0%； the bleeding complications rate were 30.8%， 17.9% respectively， the recanalization time of the treatment group was early， the recanalization rate was higher than those of the control group， the differences of the two groups were statistically significant（P 　　[Key words] Urokinase； Reteplase； Acute myocardial infarction； Fibrinolytic therapy 　　尿激酶和瑞替普酶作为当前临床普遍使用的溶栓药物，为了比较分析这两种药物对急性心肌梗死溶栓治疗的效果